These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9486100)

  • 1. Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
    ten Bokkel Huinink WW; Lustig V; Dubbelman R; Hiemstra A; Rodenhuis S
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S23-5. PubMed ID: 9486100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
    Milla-Santos A; Milla L; Rallo L; Solano V
    Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
    Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
    Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
    Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
    Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
    Spielmann M; Tubiana-Hulin M; Namer M; Mansouri H; Bougnoux Ph; Tubiana-Mathieu N; Lotz V; Eymard JC
    Br J Cancer; 2002 Mar; 86(5):692-7. PubMed ID: 11875727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
    Pagani O
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
    Bissett D; Jodrell D; Harnett AN; Habeshaw T; Kaye SB; Evans D; Williams M; Canney PA
    Br J Cancer; 1995 Jun; 71(6):1279-82. PubMed ID: 7540038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
    Ip EJ; Lee-Ma A; Troxell LS; Chan J
    Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
    Salminen E; Korpela J; Varpula M; Asola R; Varjo P; Pyrhönen S; Mali P; Hinkka S; Ekholm E
    Anticancer Drugs; 2002 Oct; 13(9):925-9. PubMed ID: 12394255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.